Practical Considerations of Tagraxofusp for Community Oncologists

This segment focuses on safety considerations associated with tagraxofusp in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), with an emphasis on early toxicity recognition in community oncology settings. Dr Luskin discusses the clinical significance of capillary leak syndrome and other treatment-related toxicities that require heightened vigilance, particularly during the initial days of therapy. She outlines how early physiologic changes may signal evolving toxicity and underscores the importance of close monitoring during the first treatment cycle. The discussion highlights practical clinical observations that can serve as early warning signs, reinforcing the need for timely assessment and intervention outside of academic centers. Dr Luskin also places these safety considerations within the broader context of BPDCN management, emphasizing how proactive monitoring and prompt response can support continued therapy while minimizing risk. Without detailing specific management protocols, this segment provides community oncologists with a framework for recognizing and responding to key toxicities associated with BPDCN-directed targeted therapy.